<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317797</url>
  </required_header>
  <id_info>
    <org_study_id>M1-1188-002-EM</org_study_id>
    <secondary_id>2010-018502-36</secondary_id>
    <secondary_id>U1111-1137-3923</secondary_id>
    <secondary_id>NL33507.058.10</secondary_id>
    <nct_id>NCT01317797</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis</brief_title>
  <acronym>PRIORA</acronym>
  <official_title>A Phase Ib Double-blind, Placebo-controlled, Randomized, Dose-escalating Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Subcutaneous Injections of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis on Treatment With Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is primarily to investigate the safety and tolerability of repeated
      subcutaneous injections of MT203 in patients with mild to moderate rheumatoid arthritis.
      Furthermore, the amount of MT203 in the blood will be measured and it will be investigated
      how the body responds to MT203 treatment and if MT203 is effective in the treatment of
      rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial medication will be administered at 2 dose levels as subcutaneous injections. Each
      patient will receive three injections in total. The trial duration consists of a screening
      period (28 - 2 days prior to the first injection) and a treatment and observation period (4
      months). The trial requires approximately 20 visits at the study site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Clinical Laboratory Results</measure>
    <time_frame>From Day 1 Up to Day 118</time_frame>
    <description>Blood was collected for Haematology, Chemistry and Coagulation. Urine was collected for Urinalysis. Alert values for laboratory results include the following: Aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyl-transpeptidase (GGT), alkaline phosphatase (AP), total bilirubin (TBil): &gt; 3 times upper limit of normal (ULN). Creatinine and Glucose: &gt; 2 times ULN. Potassium &gt; 6.0 or &lt; 3.0 mmol/L. Haemoglobin: Male &lt; 8.0 ;Female &lt; 7.0 g/dL. Erythrocytes :Male &lt; 3.5 x 10^12/L or &gt; 7 x 10^12/L;Female &lt; 3.0 x 10^12/L or &gt; 6.5 x 10^12/L. White Blood Cells (WBC): &lt; 2.8 x10^9/L or &gt; 16.0 x 10^9/L. Eosinophils &gt; 20 % of cells in the WBC differential. Platelet Count &lt; 75 x 10^9/L or 600 x 10^9/L. No alert values were identified for Coagulation or Urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>From Day 1 Up to Day 118</time_frame>
    <description>Alert values for ECG were: Heart rate &lt; 35 bpm or &gt; 120 bpm, QTc acc. to Bazett (absolute value)&gt; 500 ms or QTc acc. to Bazett (increase versus Baseline (pre-treatment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Signs</measure>
    <time_frame>From Day 1 Up to Day 118</time_frame>
    <description>Vital signs included Systolic Blood Pressure (BP), Diastolic BP, body temperature, heart rate. Alert values were: BP systolic &gt; 170 mmHg or &lt; 85 mmHg, BP diastolic &gt; 105 mmHg, Difference BP systolic vs. Baseline (pre-treatment) &gt; 40 mmHg or Pulse rate &lt; 35 bpm or &gt; 120 beats per minute (bpm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Pulmonary Function Tests</measure>
    <time_frame>From Day 1 Up to Day 118</time_frame>
    <description>Pulmonary function was determined by forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and peak flow.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examination Findings</measure>
    <time_frame>From Day 1 Up to Day 118</time_frame>
    <description>The physical examination included body system assessments: eyes, head and neck (including thyroid), ears, nose and throat, lymph nodes, cardiovascular, lungs, mammae, abdomen (liver, spleen), genitals, limbs, central and peripheral nervous system, musculoskeletal system, skin &amp; nails, mucosae. The Investigator classified abnormal findings as either clinically significant or not clinically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment Emergent Adverse Events</measure>
    <time_frame>From Day 1 Up to Day 118</time_frame>
    <description>An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MT203</measure>
    <time_frame>Day 1 and 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
    <description>Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for MT203</measure>
    <time_frame>Day 1 and 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MT203</measure>
    <time_frame>Day 1 and 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
    <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MT203</measure>
    <time_frame>Day 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
    <description>AUC(0-inf) is measure of area under the curve over the dosing interval (tau) (AUC(0-tau]), where tau is the length of the dosing interval in this study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for MT203</measure>
    <time_frame>Day 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
    <description>Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half-life (T1/2) for MT203</measure>
    <time_frame>Day 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
    <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough: Maximum Observed Plasma Concentration Pre-Dose</measure>
    <time_frame>Days 1, 15 and 29 Pre-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Plasma</measure>
    <time_frame>Baseline and Days 2, 4, 6, 8 15, 29, 30, 35, 43, 56, 71, 99, End of trial (EOT) Up to Day 118</time_frame>
    <description>MT203/GM-CSF complexes were analysed using a procedure that quantified GM-CSF after dissociation from the complex. The determined concentrations corresponded to the amount of total (free and complexed) GM-CSF in the plasma sample. A positive change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MT203/GM-CSF Complexes in Plasma</measure>
    <time_frame>Baseline and Days 2, 4, 6, 8 15, 29, 30, 35, 43, 56, 71, 99, EOT Up to Day 118</time_frame>
    <description>MT203/GM-CSF complexes were analysed using a procedure that quantified GM-CSF after dissociation from the complex. The determined concentrations corresponded to the amount of total (free and complexed) GM-CSF in the plasma sample. A positive change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-MT203 Antibodies</measure>
    <time_frame>From Day 1 Up to Day 118</time_frame>
    <description>Serum samples were tested for the presence of anti-MT203 antibodies by a bridging Electro-chemi-luminescent assay (ECL-assay).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR 20) Response</measure>
    <time_frame>Baseline and Days 13,27,43,56,71,99 and EOT Up to Day 118</time_frame>
    <description>ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant Erythrocyte Sedimentation Rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Disease Activity Score 44-Erythrocyte Sedimentation Rate (DAS44-ESR)</measure>
    <time_frame>Baseline and Days 13,27,43,56,71,99 and EOT Up to Day 118</time_frame>
    <description>Ritchie articular index (RAI); a joint count that grades the tenderness of 26 joints on a scale of 0-3); the number of swollen joints from 44 joints (swollen44); ESR in mm/hour after 1 hour and the patient's global disease activity on a Visual Analogue Scale (VAS) of 100 mm (0=no disease activity to right end of the line 100=maximum disease activity) were used to calculate DAS44-ESR using the following formula: DAS44-ESR = 0.54*sqrt(RAI) + 0.065*(swollen44) + 0.33*ln(ESR) + 0.0072*VAS. Lower numbers were better. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Namilumab 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Namilumab 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>namilumab (MT203)</intervention_name>
    <description>administered three times, subcutaneous in the abdomen</description>
    <arm_group_label>Namilumab 150 mg</arm_group_label>
    <arm_group_label>Namilumab 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administered three times, subcutaneous in the abdomen</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Out-patients with active rheumatoid arthritis (RA), according to the ACR 1987 revised
             criteria, with low to moderate disease activity (DAS28-ESR ≥ 2.6 and ≤ 5.1)

          2. Patients must be on stable doses of methotrexate (MTX) ≥ 7.5 and ≤ 25 mg/week for at
             least 12 weeks before the first injection, with appropriate folic acid supplementation

          3. Age ≥ 18 years at Screening

          4. Body weight at least 50 kg at Screening; BMI: ≥ 18.0 and ≤ 30.0 kg/m2 at Screening

          5. Negative tuberculosis test at Screening

          6. Heterosexually active male and female patients of childbearing potential are obliged
             to follow whatever contraceptive and / or breastfeeding restrictions may be required
             for their concomitant medication(s), including methotrexate.

        In addition, heterosexually active male and female patients of childbearing potential are
        required to use effective double-method contraception (one hormonal contraceptive or
        intrauterine device and one other additional contraceptive method) for 1 month before the
        first administration of the IMP, during the course of the trial, and for 6 month after the
        last injection of MT203.

        No special requirements are made for female patients proven to be post-menopausal (at least
        2 years after last menstrual period and FSH ≥ 40IU/L), surgically sterilized or
        hysterectomized. Likewise no special requirements for heterosexually active male who are
        surgical sterilized.

        Pregnant or lactating female patients have to be excluded.

        Exclusion Criteria:

          1. Participation in another clinical trial or previous dosing in this trial

          2. Use of specified medications within certain timeframes or use of certain comedications

          3. History or presence of specified diseases

          4. Drug abuse

          5. Certain laboratory parameters outside a specified range

          6. Donation of blood

          7. Relevant decrease in lung function

          8. Infections, frequent or chronic infections, herpes zoster

          9. Females: positive pregnancy test

         10. Presence of history of tuberculosis

         11. History of malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Leids</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2011</study_first_posted>
  <results_first_submitted>July 24, 2015</results_first_submitted>
  <results_first_submitted_qc>July 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2015</results_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>MT203</keyword>
  <keyword>Human IgG1 monoclonal antibody</keyword>
  <keyword>GM-CSF monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 10 investigative sites in Bulgaria, Netherlands and Spain from 09 March 2011 to 08 August 2013.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of mild or moderate rheumatoid arthritis were enrolled into 1 of 3 treatment groups namilumab (MT203) 150mg, namilumab 300 mg or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Namilumab 150 mg</title>
          <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
        </group>
        <group group_id="P2">
          <title>Namilumab 300 mg</title>
          <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Patient</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Namilumab 150 mg</title>
          <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
        </group>
        <group group_id="B2">
          <title>Namilumab 300 mg</title>
          <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="6.95"/>
                    <measurement group_id="B2" value="56.6" spread="15.28"/>
                    <measurement group_id="B3" value="53.4" spread="11.05"/>
                    <measurement group_id="B4" value="55.9" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.21" spread="8.605"/>
                    <measurement group_id="B2" value="168.57" spread="6.321"/>
                    <measurement group_id="B3" value="168.44" spread="5.126"/>
                    <measurement group_id="B4" value="167.74" spread="6.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.13" spread="7.140"/>
                    <measurement group_id="B2" value="80.44" spread="7.305"/>
                    <measurement group_id="B3" value="77.80" spread="8.617"/>
                    <measurement group_id="B4" value="75.35" spread="9.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.69" spread="2.471"/>
                    <measurement group_id="B2" value="28.30" spread="1.778"/>
                    <measurement group_id="B3" value="27.37" spread="2.246"/>
                    <measurement group_id="B4" value="26.75" spread="2.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Score</title>
          <description>The DAS28-ESR is expressed on a unit on a scale with the minimum score=0 (best) to maximum score=10 (worst).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.70" spread="0.542"/>
                    <measurement group_id="B2" value="4.66" spread="0.544"/>
                    <measurement group_id="B3" value="4.60" spread="0.512"/>
                    <measurement group_id="B4" value="4.65" spread="0.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Clinical Laboratory Results</title>
        <description>Blood was collected for Haematology, Chemistry and Coagulation. Urine was collected for Urinalysis. Alert values for laboratory results include the following: Aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyl-transpeptidase (GGT), alkaline phosphatase (AP), total bilirubin (TBil): &gt; 3 times upper limit of normal (ULN). Creatinine and Glucose: &gt; 2 times ULN. Potassium &gt; 6.0 or &lt; 3.0 mmol/L. Haemoglobin: Male &lt; 8.0 ;Female &lt; 7.0 g/dL. Erythrocytes :Male &lt; 3.5 x 10^12/L or &gt; 7 x 10^12/L;Female &lt; 3.0 x 10^12/L or &gt; 6.5 x 10^12/L. White Blood Cells (WBC): &lt; 2.8 x10^9/L or &gt; 16.0 x 10^9/L. Eosinophils &gt; 20 % of cells in the WBC differential. Platelet Count &lt; 75 x 10^9/L or 600 x 10^9/L. No alert values were identified for Coagulation or Urinalysis.</description>
        <time_frame>From Day 1 Up to Day 118</time_frame>
        <population>Safety population included all randomized participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Clinical Laboratory Results</title>
          <description>Blood was collected for Haematology, Chemistry and Coagulation. Urine was collected for Urinalysis. Alert values for laboratory results include the following: Aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyl-transpeptidase (GGT), alkaline phosphatase (AP), total bilirubin (TBil): &gt; 3 times upper limit of normal (ULN). Creatinine and Glucose: &gt; 2 times ULN. Potassium &gt; 6.0 or &lt; 3.0 mmol/L. Haemoglobin: Male &lt; 8.0 ;Female &lt; 7.0 g/dL. Erythrocytes :Male &lt; 3.5 x 10^12/L or &gt; 7 x 10^12/L;Female &lt; 3.0 x 10^12/L or &gt; 6.5 x 10^12/L. White Blood Cells (WBC): &lt; 2.8 x10^9/L or &gt; 16.0 x 10^9/L. Eosinophils &gt; 20 % of cells in the WBC differential. Platelet Count &lt; 75 x 10^9/L or 600 x 10^9/L. No alert values were identified for Coagulation or Urinalysis.</description>
          <population>Safety population included all randomized participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemistry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coagulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings</title>
        <description>Alert values for ECG were: Heart rate &lt; 35 bpm or &gt; 120 bpm, QTc acc. to Bazett (absolute value)&gt; 500 ms or QTc acc. to Bazett (increase versus Baseline (pre-treatment).</description>
        <time_frame>From Day 1 Up to Day 118</time_frame>
        <population>Safety population included all randomized participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings</title>
          <description>Alert values for ECG were: Heart rate &lt; 35 bpm or &gt; 120 bpm, QTc acc. to Bazett (absolute value)&gt; 500 ms or QTc acc. to Bazett (increase versus Baseline (pre-treatment).</description>
          <population>Safety population included all randomized participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Vital Signs</title>
        <description>Vital signs included Systolic Blood Pressure (BP), Diastolic BP, body temperature, heart rate. Alert values were: BP systolic &gt; 170 mmHg or &lt; 85 mmHg, BP diastolic &gt; 105 mmHg, Difference BP systolic vs. Baseline (pre-treatment) &gt; 40 mmHg or Pulse rate &lt; 35 bpm or &gt; 120 beats per minute (bpm).</description>
        <time_frame>From Day 1 Up to Day 118</time_frame>
        <population>Safety population included all randomized participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Vital Signs</title>
          <description>Vital signs included Systolic Blood Pressure (BP), Diastolic BP, body temperature, heart rate. Alert values were: BP systolic &gt; 170 mmHg or &lt; 85 mmHg, BP diastolic &gt; 105 mmHg, Difference BP systolic vs. Baseline (pre-treatment) &gt; 40 mmHg or Pulse rate &lt; 35 bpm or &gt; 120 beats per minute (bpm).</description>
          <population>Safety population included all randomized participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Pulmonary Function Tests</title>
        <description>Pulmonary function was determined by forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and peak flow.</description>
        <time_frame>From Day 1 Up to Day 118</time_frame>
        <population>Safety population included all randomized participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Pulmonary Function Tests</title>
          <description>Pulmonary function was determined by forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and peak flow.</description>
          <population>Safety population included all randomized participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Physical Examination Findings</title>
        <description>The physical examination included body system assessments: eyes, head and neck (including thyroid), ears, nose and throat, lymph nodes, cardiovascular, lungs, mammae, abdomen (liver, spleen), genitals, limbs, central and peripheral nervous system, musculoskeletal system, skin &amp; nails, mucosae. The Investigator classified abnormal findings as either clinically significant or not clinically significant.</description>
        <time_frame>From Day 1 Up to Day 118</time_frame>
        <population>Safety population included all randomized participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Physical Examination Findings</title>
          <description>The physical examination included body system assessments: eyes, head and neck (including thyroid), ears, nose and throat, lymph nodes, cardiovascular, lungs, mammae, abdomen (liver, spleen), genitals, limbs, central and peripheral nervous system, musculoskeletal system, skin &amp; nails, mucosae. The Investigator classified abnormal findings as either clinically significant or not clinically significant.</description>
          <population>Safety population included all randomized participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting One or More Treatment Emergent Adverse Events</title>
        <description>An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>From Day 1 Up to Day 118</time_frame>
        <population>Safety population included all randomized participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment Emergent Adverse Events</title>
          <description>An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety population included all randomized participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MT203</title>
        <description>Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax</description>
        <time_frame>Day 1 and 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MT203</title>
          <description>Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" lower_limit="3.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="5.95" lower_limit="4.0" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" lower_limit="0.1" upper_limit="8.0"/>
                    <measurement group_id="O2" value="6.00" lower_limit="1.0" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for MT203</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Day 1 and 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
        <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for MT203</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.41" lower_limit="9.988" upper_limit="18.02"/>
                    <measurement group_id="O2" value="18.76" lower_limit="13.83" upper_limit="25.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.14" lower_limit="22.02" upper_limit="33.45"/>
                    <measurement group_id="O2" value="49.99" lower_limit="40.36" upper_limit="61.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MT203</title>
        <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Day 1 and 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
        <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MT203</title>
          <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
          <units>day*μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.9" lower_limit="112.3" upper_limit="186.9"/>
                    <measurement group_id="O2" value="210.9" lower_limit="151.8" upper_limit="292.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="786.8" lower_limit="666.9" upper_limit="928.3"/>
                    <measurement group_id="O2" value="1696" lower_limit="1293" upper_limit="2225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MT203</title>
        <description>AUC(0-inf) is measure of area under the curve over the dosing interval (tau) (AUC(0-tau]), where tau is the length of the dosing interval in this study).</description>
        <time_frame>Day 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
        <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MT203</title>
          <description>AUC(0-inf) is measure of area under the curve over the dosing interval (tau) (AUC(0-tau]), where tau is the length of the dosing interval in this study).</description>
          <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
          <units>day*μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="832.8" lower_limit="708.8" upper_limit="978.4"/>
                    <measurement group_id="O2" value="1861" lower_limit="1374" upper_limit="2521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for MT203</title>
        <description>Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.</description>
        <time_frame>Day 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
        <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for MT203</title>
          <description>Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.</description>
          <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
          <units>day*μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.5" lower_limit="263.2" upper_limit="385.5"/>
                    <measurement group_id="O2" value="591.9" lower_limit="473.3" upper_limit="740.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Elimination Half-life (T1/2) for MT203</title>
        <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
        <time_frame>Day 29 (Pre-dose and 2 and 6 hours post-dose)</time_frame>
        <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Elimination Half-life (T1/2) for MT203</title>
          <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
          <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.26" lower_limit="13.7" upper_limit="34.6"/>
                    <measurement group_id="O2" value="23.68" lower_limit="18.6" upper_limit="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctrough: Maximum Observed Plasma Concentration Pre-Dose</title>
        <time_frame>Days 1, 15 and 29 Pre-dose</time_frame>
        <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough: Maximum Observed Plasma Concentration Pre-Dose</title>
          <population>PK Analysis set included all 15 participants who were exposed to study drug for whom any PK parameters could be calculated. Method of Dispersion is the 68% range.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.232" lower_limit="7.543" upper_limit="11.30"/>
                    <measurement group_id="O2" value="14.56" lower_limit="11.33" upper_limit="18.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.53" lower_limit="13.03" upper_limit="18.50"/>
                    <measurement group_id="O2" value="27.28" lower_limit="18.89" upper_limit="39.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.27" lower_limit="16.74" upper_limit="24.53"/>
                    <measurement group_id="O2" value="36.88" lower_limit="31.85" upper_limit="42.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Plasma</title>
        <description>MT203/GM-CSF complexes were analysed using a procedure that quantified GM-CSF after dissociation from the complex. The determined concentrations corresponded to the amount of total (free and complexed) GM-CSF in the plasma sample. A positive change from Baseline indicated improvement.</description>
        <time_frame>Baseline and Days 2, 4, 6, 8 15, 29, 30, 35, 43, 56, 71, 99, End of trial (EOT) Up to Day 118</time_frame>
        <population>All randomized participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Plasma</title>
          <description>MT203/GM-CSF complexes were analysed using a procedure that quantified GM-CSF after dissociation from the complex. The determined concentrations corresponded to the amount of total (free and complexed) GM-CSF in the plasma sample. A positive change from Baseline indicated improvement.</description>
          <population>All randomized participants with data available for analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (n=7, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.000"/>
                    <measurement group_id="O2" value="-0.86" spread="2.268"/>
                    <measurement group_id="O3" value="0.67" spread="2.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n=6, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="3.286"/>
                    <measurement group_id="O2" value="0.86" spread="4.140"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n=6, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="3.286"/>
                    <measurement group_id="O2" value="2.57" spread="3.207"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=6, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" spread="10.330"/>
                    <measurement group_id="O2" value="4.29" spread="2.928"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=7, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.86" spread="8.825"/>
                    <measurement group_id="O2" value="8.61" spread="8.978"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=7, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.59" spread="13.323"/>
                    <measurement group_id="O2" value="15.14" spread="6.690"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (n=6, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.68" spread="24.908"/>
                    <measurement group_id="O2" value="22.11" spread="16.954"/>
                    <measurement group_id="O3" value="0.75" spread="2.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 (n=7, 7, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.29" spread="20.203"/>
                    <measurement group_id="O2" value="25.71" spread="16.261"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (n=7, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.04" spread="18.838"/>
                    <measurement group_id="O2" value="28.10" spread="15.013"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=7, 6, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.34" spread="20.330"/>
                    <measurement group_id="O2" value="32.32" spread="14.337"/>
                    <measurement group_id="O3" value="0.75" spread="2.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (n=5, 6, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.48" spread="21.759"/>
                    <measurement group_id="O2" value="35.02" spread="12.402"/>
                    <measurement group_id="O3" value="0.75" spread="2.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 (n=7, 6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.11" spread="11.113"/>
                    <measurement group_id="O2" value="23.77" spread="8.881"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT (n=7, 6, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="7.919"/>
                    <measurement group_id="O2" value="17.38" spread="10.745"/>
                    <measurement group_id="O3" value="0.67" spread="2.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MT203/GM-CSF Complexes in Plasma</title>
        <description>MT203/GM-CSF complexes were analysed using a procedure that quantified GM-CSF after dissociation from the complex. The determined concentrations corresponded to the amount of total (free and complexed) GM-CSF in the plasma sample. A positive change from Baseline indicated improvement.</description>
        <time_frame>Baseline and Days 2, 4, 6, 8 15, 29, 30, 35, 43, 56, 71, 99, EOT Up to Day 118</time_frame>
        <population>All randomized participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MT203/GM-CSF Complexes in Plasma</title>
          <description>MT203/GM-CSF complexes were analysed using a procedure that quantified GM-CSF after dissociation from the complex. The determined concentrations corresponded to the amount of total (free and complexed) GM-CSF in the plasma sample. A positive change from Baseline indicated improvement.</description>
          <population>All randomized participants with data available for analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (n=8, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" spread="63.92"/>
                    <measurement group_id="O2" value="12.7" spread="16.25"/>
                    <measurement group_id="O3" value="-0.2" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n=8, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.6" spread="183.16"/>
                    <measurement group_id="O2" value="186.1" spread="100.15"/>
                    <measurement group_id="O3" value="-0.6" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n=8, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381.6" spread="152.52"/>
                    <measurement group_id="O2" value="334.6" spread="89.19"/>
                    <measurement group_id="O3" value="-1.3" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=8, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448.0" spread="110.76"/>
                    <measurement group_id="O2" value="534.1" spread="80.58"/>
                    <measurement group_id="O3" value="-1.3" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=8, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1021.0" spread="353.03"/>
                    <measurement group_id="O2" value="1055.0" spread="124.65"/>
                    <measurement group_id="O3" value="-3.9" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=8, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1566.9" spread="391.80"/>
                    <measurement group_id="O2" value="1805.4" spread="150.43"/>
                    <measurement group_id="O3" value="-4.4" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (n=8, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1653.5" spread="498.31"/>
                    <measurement group_id="O2" value="1834.9" spread="178.71"/>
                    <measurement group_id="O3" value="-4.4" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 (n=8, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1796.9" spread="560.58"/>
                    <measurement group_id="O2" value="2052.9" spread="294.95"/>
                    <measurement group_id="O3" value="-4.4" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (n=8, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2213.0" spread="744.37"/>
                    <measurement group_id="O2" value="2290.6" spread="282.35"/>
                    <measurement group_id="O3" value="-4.4" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=8, 6, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2009.0" spread="614.92"/>
                    <measurement group_id="O2" value="2457.2" spread="466.01"/>
                    <measurement group_id="O3" value="-4.4" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (n=8, 6, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1299.6" spread="313.20"/>
                    <measurement group_id="O2" value="2312.2" spread="492.50"/>
                    <measurement group_id="O3" value="-4.4" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 (n=8, 6, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462.6" spread="275.40"/>
                    <measurement group_id="O2" value="1753.5" spread="351.34"/>
                    <measurement group_id="O3" value="-4.4" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT (n=8, 6, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.4" spread="144.03"/>
                    <measurement group_id="O2" value="1310.8" spread="460.45"/>
                    <measurement group_id="O3" value="-3.9" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-MT203 Antibodies</title>
        <description>Serum samples were tested for the presence of anti-MT203 antibodies by a bridging Electro-chemi-luminescent assay (ECL-assay).</description>
        <time_frame>From Day 1 Up to Day 118</time_frame>
        <population>Safety population included all randomized participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-MT203 Antibodies</title>
          <description>Serum samples were tested for the presence of anti-MT203 antibodies by a bridging Electro-chemi-luminescent assay (ECL-assay).</description>
          <population>Safety population included all randomized participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR 20) Response</title>
        <description>ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient’s Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient’s Global Assessment of Disease Activity and Physician’s Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant Erythrocyte Sedimentation Rate.</description>
        <time_frame>Baseline and Days 13,27,43,56,71,99 and EOT Up to Day 118</time_frame>
        <population>All randomized participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR 20) Response</title>
          <description>ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient’s Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient’s Global Assessment of Disease Activity and Physician’s Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant Erythrocyte Sedimentation Rate.</description>
          <population>All randomized participants with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Disease Activity Score 44-Erythrocyte Sedimentation Rate (DAS44-ESR)</title>
        <description>Ritchie articular index (RAI); a joint count that grades the tenderness of 26 joints on a scale of 0-3); the number of swollen joints from 44 joints (swollen44); ESR in mm/hour after 1 hour and the patient’s global disease activity on a Visual Analogue Scale (VAS) of 100 mm (0=no disease activity to right end of the line 100=maximum disease activity) were used to calculate DAS44-ESR using the following formula: DAS44-ESR = 0.54*sqrt(RAI) + 0.065*(swollen44) + 0.33*ln(ESR) + 0.0072*VAS. Lower numbers were better. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline and Days 13,27,43,56,71,99 and EOT Up to Day 118</time_frame>
        <population>All randomized participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Namilumab 150 mg</title>
            <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O2">
            <title>Namilumab 300 mg</title>
            <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Disease Activity Score 44-Erythrocyte Sedimentation Rate (DAS44-ESR)</title>
          <description>Ritchie articular index (RAI); a joint count that grades the tenderness of 26 joints on a scale of 0-3); the number of swollen joints from 44 joints (swollen44); ESR in mm/hour after 1 hour and the patient’s global disease activity on a Visual Analogue Scale (VAS) of 100 mm (0=no disease activity to right end of the line 100=maximum disease activity) were used to calculate DAS44-ESR using the following formula: DAS44-ESR = 0.54*sqrt(RAI) + 0.065*(swollen44) + 0.33*ln(ESR) + 0.0072*VAS. Lower numbers were better. A negative change from Baseline indicated improvement.</description>
          <population>All randomized participants with data available for analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 13 (n=8, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.473" spread="0.7412"/>
                    <measurement group_id="O2" value="-0.310" spread="0.5369"/>
                    <measurement group_id="O3" value="-0.344" spread="0.6491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 27 (n=8, 7, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.798" spread="0.6432"/>
                    <measurement group_id="O2" value="-0.995" spread="0.7094"/>
                    <measurement group_id="O3" value="-0.383" spread="0.7425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (n=8, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.873" spread="0.6064"/>
                    <measurement group_id="O2" value="-0.852" spread="0.8223"/>
                    <measurement group_id="O3" value="-0.469" spread="0.6585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=8, 6, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.002" spread="0.9624"/>
                    <measurement group_id="O2" value="-1.190" spread="0.8217"/>
                    <measurement group_id="O3" value="-1.184" spread="1.0178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (n=7, 6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.853" spread="0.4461"/>
                    <measurement group_id="O2" value="-0.980" spread="0.7478"/>
                    <measurement group_id="O3" value="-1.134" spread="1.1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 (n=8, 6, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.678" spread="0.4345"/>
                    <measurement group_id="O2" value="-0.914" spread="0.7782"/>
                    <measurement group_id="O3" value="-1.025" spread="0.8533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT (n=8, 6, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.591" spread="0.5664"/>
                    <measurement group_id="O2" value="-0.974" spread="0.5992"/>
                    <measurement group_id="O3" value="-1.138" spread="0.9667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 Up to Day 118</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Namilumab 150 mg</title>
          <description>Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.</description>
        </group>
        <group group_id="E2">
          <title>Namilumab 300 mg</title>
          <description>Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non-small cell lung cancer stage IIIa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Haemoglobin urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mean cell volume increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

